Description: Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. Timber is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), tuberous sclerosis complex (TSC), and localized scleroderma.
Home Page: www.timberpharma.com
TMBR Technical Analysis
110 Allen Road
Basking Ridge,
NJ
07920
United States
Phone:
973 314 9577
Officers
| Name | Title |
|---|---|
| Mr. John Koconis M.B.A. | Chairman, CEO & Pres |
| Mr. Joseph Lucchese | Exec. VP, CFO, Treasurer & Sec. |
| Dr. Alan Mendelsohn M.D. | Exec. VP & Chief Medical Officer |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6151 |
| Price-to-Sales TTM: | 17.1859 |
| IPO Date: | 2015-06-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |